The research and development process of Novartis and the introduction of Wuhan Novartis Biotechnology Co., Ltd.
In the 1960s, in the tropical rain forest of the Vietnam battlefield, a large number of American soldiers were injured and their wounds ulcerated, making it difficult to heal. As a result, the U.S. government spent huge sums of money and gathered a large number of scientific researchers to focus on developing new materials that can quickly heal soft tissue ulcers, repair damaged bone tissue, and firmly bond the two. In 1971, Larry Hench, an American biomaterials scientist, chief expert of the Federal Institute of Medicine, and professor at the University of Florida, discovered NovaMin in a bone regeneration composite invention and developed it. The world's only "nosamine bioactive glass material" that can repair and bond soft tissue and bone tissue at the same time, won the Nobel Prize in Medicine that year. Novartis bioactive glass is a new implantable material that is fully accepted by the human body's regenerative system. Novartis bioactive glass has been awarded four global patents and has been widely used in more than one million implant operations.
PerioGlas developed by USBiomaterials Corporation (USB)/NovaMin Technology, Inc (NTI), (Alachua 32615, Florida, USA) using NovaMin bioactive glass materials (Beijiansheng, the domestic price is about 1,500 yuan/gram), NovaBone (Gujiansheng, the domestic price is about 2,000 yuan/gram) is an orthopedic tissue repair material, used for the repair of various bone defects and fractures Healing; Dermglas (dermglass, quoted at about 180 yuan/gram in China) developed using Novartis bioactive glass material is a soft tissue injury healing product, used for the healing of various skin ulcers, erosions and other wounds, with remarkable results . These products have been in clinical use worldwide for many years.
In August 2002, USBiomaterials Corporation (USB)/NovaMin Technology, Inc (NTI), (Alachua 32615, Florida, USA) was registered and established in China as an independent company. The R&D and production base in Wuhan - Wuhan Libaisheng Technology Co., Ltd. (the predecessor of Wuhan Novartis Biotechnology Co., Ltd.) uses the patented technology of Novartis from the United States and pure bioactive glass raw materials from Novartis from the United States to simultaneously produce Orwell ( Oravive toothpaste (all exported to foreign markets) and NovaMin toothpaste (exclusively for sale in China)
In 2003, NovaMin began to enter the Wuhan University Stomatological Hospital and the Affiliated Hubei College of Traditional Chinese Medicine. The hospital conducted clinical verification until the end of 2006, which lasted 2 years and achieved satisfactory clinical results.
In January 2006, Wuhan Libaisheng Technology Co., Ltd. was renamed: Wuhan Novartis Biotechnology Co., Ltd. On April 25 of the same year, Novartis obtained the medical device registration certificate from the China Food and Drug Administration (registration Certificate number: Hubei Food and Drug Administration (Approved) No.: 2006 No. 2630929) is the earliest and only drug approved by the Food and Drug Administration for oral tooth repair, anti-inflammation and hemostasis, healing of oral ulcer wounds, sealing of dentinal tubules, and elimination of tooth decay. A new oral bioactive glass material product for patients with intrinsic allergies. It has great effects on tooth allergy, gum bleeding, gum recession, loose teeth, pickled teeth, dental fluorosis, dental caries, yellowing of tooth enamel, oral ulcers, oral odor, etc. Good effect. Novartis bioactive glass toothpaste does not contain fluorine, is sterile, is safe to use, and is more suitable for long-term use by children and pregnant women. From 2006 to the present, Novartis has been sold well in most parts of China, and Orwell has been exported overseas without any cases. Clinical adverse reactions and quality complaints occur, and its precise efficacy is favored by clinicians and patients around the world.
In August 2008, Novartis Biotechnology Co., Ltd. officially settled in Wuhan Economic and Technological Development Zone, a national development zone, and built new factories and production workshops in accordance with national GMP standards. Currently, Wuhan Novartis Biotechnology Co., Ltd. It holds the "Novarmin" trademark (the "Orwell" trademark is held by Novartis Technology Company of the United States), and has the world's most advanced automated toothpaste production line and testing equipment with an annual output of 12 million pieces.
In May 2009, Novartis's quality standards were upgraded globally (the new standard: YZB/E 0307-2009 replaced the old standard: YZB/E 0307-2004). The products were further concentrated on the original basis, and the quality was greatly improved. Improved and re-obtained the medical device registration certificate from the Food and Drug Administration (new registration number: E Food and Drug Administration (Approved) Zi 2009 No. 2631248). At the same time, the Food and Drug Administration approved the trade name of Novartis Bioactive Glass Tooth Reinforcement Paste. For: Novartis.
The quality policy of Wuhan Novum Biotechnology Co., Ltd.: Take international standards as management guidelines and serve the cause of human health.
Remarks: 1. Not all bioactive glasses are called nosamine. Only the American nosamine bioactive glass has good repairing and bonding effects on bone tissue and soft tissue.
2. The global Novartis bioactive glass toothpaste (application in the oral field) was first developed and produced in China
by an American company using Novartis patented technology and raw materials. And sold all over the world, China launched it earlier than other countries in the world.
3. The quality of Novartis bioactive glass toothpaste will always be consistent with the quality of global products, and standard upgrades will be carried out globally.